April 28, 2021 03:47 PM EDTUpdated April 29, 05:53 AM

ODAC votes to keep Keytruda and Tecentriq accelerated approvals in bladder cancer

Zachary Brennan

Senior Editor

The FDA’s Oncologic Drugs Advisory Committee is continuing to find it difficult to say no to cancer patients, especially as bladder cancer patients affected by …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ODAC votes to keep Keytruda and Tecentriq accelerated approvals in bladder cancer

Zachary Brennan

Senior Editor

Sign up to read this article for free.

New fund will pressure flailing biotechs, as investor frustration boils over

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

Merck KGaA closes in on SpringWorks deal at $3.5B price point

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

ODAC votes to keep Keytru­da and Tecen­triq ac­cel­er­at­ed ap­provals in blad­der can­cer

Zachary Brennan

Senior Editor

Sign up to read this article for free.

New fund will pres­sure flail­ing biotechs, as in­vestor frus­tra­tion boils over

Ake­so shares new da­ta sug­gest­ing it can beat Keytru­da on sur­vival, wins Chi­na ap­proval

Cari­bou lays off 32% of staff, cuts lu­pus cell ther­a­py pro­gram be­fore first pa­tient

Ab­b­Vie com­mits $10B to ex­pand US foot­print with the threat of tar­iffs ahead

Mer­ck KGaA clos­es in on Spring­Works deal at $3.5B price point

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

ODAC votes to keep Keytruda and Tecentriq accelerated approvals in bladder cancer

New fund will pressure flailing biotechs, as investor frustration boils over

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

Merck KGaA closes in on SpringWorks deal at $3.5B price point

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence